Tumor-associated ligands recognized by γδ TCR

Tumor-associated ligands recognized by γδ TCR are a heterogeneous group of molecules that serve as 'stressed-self' signals to activate γδ T cells, a specialized subset of lymphocytes bridging innate and adaptive immunity. Unlike conventional αβ T cells, which require MHC-restricted peptide presentation, γδ T cells recognize these ligands directly or through specialized accessory molecules, allowing them to bypass common tumor escape mechanisms like MHC downregulation. The most prominent ligands include phosphoantigens (pAgs) such as isopentenyl pyrophosphate (IPP), which are sensed via the butyrophilin 3A1 (BTN3A1) and BTN2A1 complex by Vγ9Vδ2 T cells, and MHC class I-related molecules (MICA and MICB) recognized by Vδ1 T cells. In the context of malignancy, these ligands are often upregulated due to metabolic dysregulation or oncogenic stress, triggering γδ T cells to eliminate tumor cells through direct cytotoxicity (perforin/granzyme release) and the secretion of pro-inflammatory cytokines like IFN-γ and TNF-α. Therapeutic strategies targeting these interactions include amino-bisphosphonates to induce phosphoantigen accumulation, monoclonal antibodies to modulate butyrophilin conformation, and bispecific γδ T-cell engagers designed to harness the potent anti-tumor activity of these cells.

Other names

γδ TCR ligandsGamma-delta T-cell receptor ligandsStress-induced ligandsNon-peptide antigensPhosphoantigens (pAgs)Butyrophilins (BTN3A1, BTN2A1)MHC class I-related chain A/B (MICA/B)UL16-binding proteins (ULBPs)CD1cEndothelial protein C receptor (EPCR)Annexin A2Ephrin type-A receptor 2 (EphA2)

Activation of γδ T cells through direct TCR binding or modulation of surface accessory molecules (e.g., butyrophilins) to induce MHC-independent tumor cell lysis and inflammatory cytokine production.